ArticleClinical and translational radiation oncology2026
European lung cancer congress 2026 - the thoracic radiation oncologist's view.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This summary statement of the European Lung Cancer Conference (ELCC) 2026 presents an overview of current debates in thoracic oncology from the radiation therapy perspective. A major topic of interest in small cell lung cancer (SCLC) were bispecific T-cell engagers (biTe) in extensive stage carcinomas, especially the use of Tarlatamab. Non-small cell lung cancer (NSCLC) was discussed from the viewpoint of multidisciplinary decision making as investigated in the MDT-Bridge study. Another focus was placed on platform drug-RT trials, such as the CONCORDE study. As for thymomas and thymic cancers, the retrospective evidence available to date was summed up with three ongoing trials for PORT expected to finish recruitment within the next five years. The role of SBRT in oligometastatic disease as local ablative treatment, either as a strategy to delay the shift to the next line of systemic treatment or - upfront - in order to block oligoprogression, was discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.